

Influence of Renal Impairment on the Pharmacokinetic Dabigatran Etexilate

Clinical Pharmacokinetics

49, 259-268

DOI: 10.2165/11318170-000000000-00000

Citation Report

#	ARTICLE	IF	CITATIONS
1	Bridging therapy and oral anticoagulation: current and future prospects. Current Opinion in Hematology, 2010, 17, 444-449.	2.5	28
2	Dabigatran etexilate â€“ a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis and Haemostasis, 2010, 103, 1116-1127.	3.4	1,330
3	Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1885-1889.	2.4	198
4	Advances in oral anticoagulants: focus on dabigatran etexilate. Expert Review of Clinical Pharmacology, 2010, 3, 727-737.	3.1	2
5	Dabigatran Etexilate. American Journal of Cardiovascular Drugs, 2011, 11, 57-72.	2.2	36
6	Dabigatran etexilate: a guide to its use in the prevention of thromboembolic disorders. Drugs and Therapy Perspectives, 2011, 27, 1-8.	0.6	0
7	Dabigatran Etexilate. Circulation, 2011, 123, 1436-1450.	1.6	340
9	Safety and Efficacy of Antiplatelet and Antithrombotic Therapy in Acute Coronary Syndrome Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2011, 58, 2263-2269.	2.8	45
10	Spotlight on Dabigatran Etexilate in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillationâ€“. Drugs and Aging, 2011, 28, 415-419.	2.7	1
11	Use of Low-Molecular-Weight Heparins and New Anticoagulants in Elderly Patients with Renal Impairment. Drugs and Aging, 2011, 28, 177-193.	2.7	32
13	Dabigatran etexilate: A novel oral direct thrombin inhibitor. American Journal of Health-System Pharmacy, 2011, 68, 1506-1519.	1.0	49
14	Dabigatran Etexilate: A Novel Oral Thrombin Inhibitor for Thromboembolic Disease. Annals of Pharmacotherapy, 2011, 45, 603-614.	1.9	13
15	Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: A subgroup analysis from the AURICULA registry in Sweden. Thrombosis Research, 2011, 128, 341-345.	1.7	24
16	Advances in Anticoagulation: Focus on Dabigatran, an Oral Direct Thrombin Inhibitor. Journal of Cardiothoracic and Vascular Anesthesia, 2011, 25, 1208-1212.	1.3	13
17	Management of Bleeding Complications in the Anticoagulated Patient. Seminars in Hematology, 2011, 48, 285-294.	3.4	9
18	Prevention and Treatment of Venous Thromboembolic Events: Focus on Dabigatran Etexilate. Clinical Medicine Insights Therapeutics, 2011, 3, CMT.S1176.	0.4	0
19	Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation.. Thrombosis and Haemostasis, 2011, 106, 868-876.	3.4	158
20	Dabigatran and other oral antithrombotic agents for the prevention of stroke in patients with atrial fibrillation. Research Reports in Clinical Cardiology, 2011, , 71.	0.2	1

#	ARTICLE	IF	CITATIONS
21	Disorders of the pulmonary circulation. Current Opinion in Pulmonary Medicine, 2011, 17, 379.	2.6	1
22	Antithrombotic Therapy in Atrial Fibrillation - Evaluation and Positioning of New Oral Anticoagulant Agents -. Circulation Journal, 2011, 75, 1539-1547.	1.6	53
23	Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. Journal of Thrombosis and Haemostasis, 2011, 9, 1652-1653.	3.8	35
24	Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with nonâ€œvalvular atrial fibrillation from the REâ€œLY trial. Journal of Thrombosis and Haemostasis, 2011, 9, 2168-2175.	3.8	271
25	Direct Thrombin Inhibitors for the Treatment of Venous Thromboembolism: Analysis of the Dabigatran versus Warfarin Clinical Trial. Seminars in Vascular Surgery, 2011, 24, 157-161.	2.8	3
26	Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness. Pharmacotherapy, 2011, 31, 1232-1249.	2.6	31
27	Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thrombosis and Haemostasis, 2011, 105, 371-378.	3.4	276
28	Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. Journal of Thrombosis and Thrombolysis, 2011, 31, 326-343.	2.1	211
29	Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. Advances in Therapy, 2011, 28, 460-472.	2.9	15
30	Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant. Journal of Medical Toxicology, 2011, 7, 281-287.	1.5	115
31	Pharmacological basis and clinical evidence of dabigatran therapy. Journal of Hematology and Oncology, 2011, 4, 53.	17.0	15
32	Practical aspects of the oral new anticoagulants. American Journal of Hematology, 2011, 86, 586-590.	4.1	25
33	Dabigatran Etexilate: A Possible Replacement for Heparinoids and Vitamin K Antagonists?. Hospital Practice (1995), 2011, 39, 105-125.	1.0	3
34	Dabigatran. Critical Pathways in Cardiology, 2011, 10, 117-127.	0.5	11
35	Reversal of New Oral Anticoagulants. Circulation, 2011, 124, 1508-1510.	1.6	31
36	Hospital-Based Clinical Implications of the Novel Oral Anticoagulant, Dabigatran Etexilate, in Daily Practice. Hospital Practice (1995), 2011, 39, 23-34.	1.0	4
37	Efficacy and safety of novel anticoagulants compared with established agents. Therapeutic Advances in Hematology, 2011, 2, 175-195.	2.5	13
38	Dabigatran. Hospital Pharmacy, 2011, 46, 196-207.	1.0	1

#	ARTICLE	IF	CITATIONS
39	Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. <i>European Heart Journal</i> , 2011, 32, 2781-2789.	2.2	487
40	Management of coagulation. <i>Current Opinion in Anaesthesiology</i> , 2012, 25, 86-95.	2.0	4
41	Newer Anticoagulants in Cardiovascular Disease. <i>Cardiology in Review</i> , 2012, 20, 209-221.	1.4	24
42	Disorders of the pulmonary circulation. <i>Current Opinion in Pulmonary Medicine</i> , 2012, 18, 391-392.	2.6	0
43	Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1646-1650.	1.0	61
44	Dabigatran (Pradaxa). <i>American Journal of Neuroradiology</i> , 2012, 33, 426-428.	2.4	11
45	The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 07-15.	2.7	17
46	Rectal Bleeding and Hemostatic Disorders Induced by Dabigatran Etexilate in 2 Elderly Patients. <i>Annals of Pharmacotherapy</i> , 2012, 46, e14-e14.	1.9	32
47	Pharmacokinetic and Clinical Implications of Dabigatran Use in Severe Renal Impairment for Stroke Prevention in Nonvalvular Atrial Fibrillation. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1105-1110.	1.9	16
48	Safe Use of Hemodialysis for Dabigatran Removal before Cardiac Surgery. <i>Annals of Pharmacotherapy</i> , 2012, 46, e21-e21.	1.9	69
49	Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation. <i>Pharmaceuticals</i> , 2012, 5, 155-168.	3.8	7
50	Novel anticoagulants in atrial fibrillation stroke prevention. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 123-136.	2.5	16
51	Letter by Van de Werf et al Regarding Article, "Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians" <i>Stroke</i> , 2012, 43, e46-7; author reply e49.	2.0	0
52	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2012, 14, 8-27.	1.7	193
53	Stroke Prevention in Atrial Fibrillation: Concepts and Controversies. <i>Current Cardiology Reviews</i> , 2012, 8, 290-301.	1.5	12
54	A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2012, 107, 775-785.	3.4	40
55	Management of dabigatran-induced anticoagulation in trauma and acute care surgery patients. <i>Journal of Trauma and Acute Care Surgery</i> , 2012, 73, 1064-1069.	2.1	10
57	Dabigatran etexilate for the prevention of stroke in patients with nonvalvular atrial fibrillation. <i>Clinical Practice (London, England)</i> , 2012, 9, 629-637.	0.1	0

#	ARTICLE	IF	CITATIONS
58	A New Era of Antithrombotic Therapy in Patients With Atrial Fibrillation. American Journal of the Medical Sciences, 2012, 344, 128-135.	1.1	2
59	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. Journal of Thrombosis and Haemostasis, 2012, 10, 1979-1987.	3.8	29
60	Decrease in the oral bioavailability of dabigatran etexilate after coadministration with rifampicin. British Journal of Clinical Pharmacology, 2012, 74, 490-500.	2.4	103
61	Hospital Budget Implications of Substituting Dabigatran for Warfarin in an Anticoagulation Service. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 181-184.	1.7	8
62	The Management of Anticoagulants Perioperatively. Thoracic Surgery Clinics, 2012, 22, 29-34.	1.0	4
63	Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial. Expert Opinion on Pharmacotherapy, 2012, 13, 1101-1111.	1.8	9
64	Renal Profiles of Anticoagulants. Journal of Clinical Pharmacology, 2012, 52, 964-975.	2.0	40
65	Dabigatran-Induced Gastrointestinal Bleeding in an Elderly Patient with Moderate Renal Impairment. Annals of Pharmacotherapy, 2012, 46, 608-608.	1.9	97
66	How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood, 2012, 120, 2954-2962.	1.4	331
68	Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention. Thrombosis and Haemostasis, 2012, 108, 579-581.	3.4	10
69	Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood, 2012, 119, 2172-2174.	1.4	219
70	Hemorrhagic complications associated with dabigatran use. Clinical Toxicology, 2012, 50, 854-857.	1.9	46
71	How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood, 2012, 119, 3016-3023.	1.4	226
72	Clinical Challenges in a Patient With Dabigatran-Induced Fatal Hemorrhage. American Journal of Geriatric Pharmacotherapy, 2012, 10, 160-163.	3.0	67
73	Dabigatran for patients with a mechanical valve. Heart Lung and Circulation, 2012, 21, 121.	0.4	0
74	Anti-stroke prophylaxis – the ethics of collateral damage. Journal of Clinical Neuroscience, 2012, 19, 792-794.	1.5	8
75	Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?. British Journal of Clinical Pharmacology, 2012, 74, 734-740.	2.4	15
76	Optimizing the dose of dabigatran etexilate. British Journal of Clinical Pharmacology, 2012, 74, 741-743.	2.4	3

#	ARTICLE	IF	CITATIONS
77	Dabigatran Etxilate. Drugs, 2012, 72, 963-986.	10.9	23
78	New Oral Anticoagulants. Drugs, 2012, 72, 1739-1753.	10.9	76
79	Management of Bleeding in Patients Receiving Conventional or New Anticoagulants. Drugs, 2012, 72, 1965-1975.	10.9	11
80	Novel Oral Anticoagulation in Management of Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 476-486.	1.7	1
81	Dabigatran Etxilate. Pharmacoeconomics, 2012, 30, 841-855.	3.3	16
82	Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nature Reviews Nephrology, 2012, 8, 569-578.	9.6	72
83	Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. Thrombosis and Haemostasis, 2012, 107, 260-269.	3.4	30
84	Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. American Journal of Emergency Medicine, 2012, 30, 2082.e1-2082.e2.	1.6	20
86	Dabigatran in Clinical Practice. Clinical Therapeutics, 2012, 34, 2051-2060.	2.5	14
87	New anticoagulants for treatment of venous thromboembolism. European Journal of Internal Medicine, 2012, 23, 692-695.	2.2	30
88	Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012, 113, 431-441.	0.4	70
89	Dabigatran Etxilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation. Journal of Clinical Pharmacology, 2012, 52, 1373-1378.	2.0	78
91	Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thrombosis and Haemostasis, 2012, 107, 838-847.	3.4	201
92	Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?. Thrombosis, 2012, 2012, 1-9.	1.4	12
93	Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban. Thrombosis, 2012, 2012, 1-10.	1.4	12
94	Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting. Thrombosis and Haemostasis, 2012, 107, 51-58.	3.4	13
95	Oral Anticoagulant Therapy. Chest, 2012, 141, e44S-e88S.	0.8	1,323
96	Dabigatran etexilate: What do hospitalists need to know?. Journal of Hospital Medicine, 2012, 7, 262-269.	1.4	4

#	ARTICLE	IF	CITATIONS
97	Antithrombotic Therapy in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2012, 125, 2649-2661.	1.6	127
98	Blood component support in acquired coagulopathic conditions: Is there a method to the madness?. <i>American Journal of Hematology</i> , 2012, 87, S56-62.	4.1	15
99	Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. <i>American Journal of Hematology</i> , 2012, 87, S141-5.	4.1	320
100	Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. <i>Circulation</i> , 2012, 126, 343-348.	1.6	494
102	Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 340-347.	1.9	15
103	The Use of Dabigatran Immediately After Atrial Fibrillation Ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 264-268.	1.7	112
104	Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for the Management of Thromboembolic Disorders. <i>Clinical Therapeutics</i> , 2012, 34, 766-787.	2.5	18
105	Reversal of drug-induced anticoagulation: old solutions and new problems. <i>Transfusion</i> , 2012, 52, 45S-55S.	1.6	59
106	Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with nonvalvular atrial fibrillation from the RE-LY trial: reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 502-504.	3.8	1
107	Acute Stroke Management in Patients Taking Dabigatran. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 616-622.	3.9	7
108	Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment. <i>Neurocritical Care</i> , 2012, 16, 203-209.	2.4	32
109	Positive Outcome After Intentional Overdose of Dabigatran. <i>Journal of Medical Toxicology</i> , 2013, 9, 192-195.	1.5	40
110	Optimizing the Use of Anticoagulants (Heparins and Oral Anticoagulants) in the Elderly. <i>Drugs and Aging</i> , 2013, 30, 687-699.	2.7	17
111	Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 37, 223-231.	1.3	33
112	Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 171-182.	1.7	20
113	Bleeding and antidotes in new oral anticoagulants. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 191-202.	1.7	84
114	Antiplatelet medications and evolving antithrombotic medication. <i>Skeletal Radiology</i> , 2013, 42, 753-764.	2.0	1
115	Oral anticoagulants in older adults with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 403-415.	2.1	3

#	ARTICLE	IF	CITATIONS
116	Reversal of target-specific oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 195-202.	2.1	36
117	Target specific oral anticoagulants in the management of thromboembolic disease in the elderly. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 203-211.	2.1	3
118	Practical issues, limitations, and periprocedural management of the NOACs. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 212-222.	2.1	29
119	Pharmacometric Characterization of Dabigatran Hemodialysis. <i>Clinical Pharmacokinetics</i> , 2013, 52, 453-462.	3.5	40
120	Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etxilate in Patients with Hepatic Impairment. <i>Clinical Pharmacokinetics</i> , 2013, 52, 243-254.	3.5	106
121	Established and new-generation antithrombotic drugs in patients with cirrhosis – Possibilities and caveats. <i>Journal of Hepatology</i> , 2013, 59, 358-366.	3.7	107
122	Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. <i>Circulation</i> , 2013, 128, 2325-2332.	1.6	257
123	Hemorrhagic Gastritis with Dabigatran in a Patient with Renal Insufficiency. <i>Journal of Emergency Medicine</i> , 2013, 44, e221-e225.	0.7	28
125	Novel anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 677-689.	3.1	6
126	Assessment of Anticoagulation Intensity and Management of Bleeding With Old and New Oral Anticoagulants. <i>Canadian Journal of Cardiology</i> , 2013, 29, S34-S44.	1.7	40
127	Management of atrial fibrillation in chronic kidney disease: Double trouble. <i>American Heart Journal</i> , 2013, 166, 230-239.	2.7	34
128	Stroke Prevention in Atrial Fibrillation Patients With Chronic Kidney Disease. <i>Canadian Journal of Cardiology</i> , 2013, 29, S71-S78.	1.7	75
129	New oral anticoagulants and regional anaesthesia. <i>British Journal of Anaesthesia</i> , 2013, 111, i96-i113.	3.4	72
130	The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature. <i>Thrombosis Journal</i> , 2013, 11, 18.	2.1	19
131	New Oral Anticoagulants in Non-Valvular Atrial Fibrillation. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 53-60.	2.2	3
132	Management of Intracerebral Hemorrhage in the Presence of Anticoagulant Therapy. <i>Topics in Stroke Rehabilitation</i> , 2013, 20, 131-138.	1.9	1
133	Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 382-393.	1.6	281
135	Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 163-174.	2.1	18

#	ARTICLE	IF	CITATIONS
136	Treat anticoagulant-associated bleeding on the basis of bleeding severity and the availability of reversal agents. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 77-81.	0.6	0
137	Anticoagulants, renal failure and atrial fibrillation. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 1-3.	2.4	8
138	Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1029-1049.	1.5	4
139	Management of bleeding and reversal strategies for oral anticoagulants: Clinical practice considerations. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1914-1929.	1.0	49
140	Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. <i>Critical Care</i> , 2013, 17, 230.	5.8	46
141	Pharmacologic interventions for reversing the effects of oral anticoagulants. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, S12-S21.	1.0	42
142	Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding. <i>Circulation</i> , 2013, 127, 1404-1412.	1.6	222
143	New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists. <i>Clinical Pharmacokinetics</i> , 2013, 52, 69-82.	3.5	172
144	Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. <i>Heart Rhythm</i> , 2013, 10, 483-489.	0.7	139
145	Dabigatran for Anticoagulation in Atrial Fibrillation “ Early Clinical Experience in a Hospital Population and Comparison to Trial Data. <i>Heart Lung and Circulation</i> , 2013, 22, 50-55.	0.4	16
146	Acute management of bleeding in patients on novel oral anticoagulants. <i>European Heart Journal</i> , 2013, 34, 489-498.	2.2	152
147	The Evolution of Oral Anticoagulant Therapy. <i>Primary Care - Clinics in Office Practice</i> , 2013, 40, 109-134.	1.6	6
148	Contemporary Anticoagulation Reversal. <i>Journal of Pharmacy Practice</i> , 2013, 26, 43-51.	1.0	6
150	Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. <i>Journal of Cardiology</i> , 2013, 62, 121-126.	1.9	30
151	Managing Bleeding in Anticoagulated Patients in the Emergency Care Setting. <i>Journal of Emergency Medicine</i> , 2013, 45, 467-477.	0.7	21
152	Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. <i>Journal of the Neurological Sciences</i> , 2013, 331, 90-93.	0.6	34
153	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2013, 15, 625-651.	1.7	721
154	Managing Blunt Trauma in Patients Receiving Dabigatran Etexilate: Case Study and Review of the Literature. <i>Journal of Emergency Nursing</i> , 2013, 39, 302-308.	1.0	4

#	ARTICLE	IF	CITATIONS
155	Thrombin inhibitors: surgical considerations and pharmacology. ANZ Journal of Surgery, 2013, 83, 215-221.	0.7	8
156	Guideline on the management of bleeding in patients on antithrombotic agents. British Journal of Haematology, 2013, 160, 35-46.	2.5	197
157	Effective elimination of dabigatran by haemodialysis. Thrombosis and Haemostasis, 2013, 109, 596-605.	3.4	184
158	Dabigatran Etxilate: Management In Acute Ischemic Stroke. American Journal of Critical Care, 2013, 22, 169-176.	1.6	9
159	Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies. Lancet Neurology, The, 2013, 12, 394-405.	10.2	52
160	New Oral Anticoagulants in Elderly Patients with Atrial Fibrillation. American Journal of Medicine, 2013, 126, 289-296.	1.5	36
161	Reversal of Oral Anticoagulation. Pharmacotherapy, 2013, 33, 1199-1213.	2.6	21
162	Hemodialysis for the Treatment of Pulmonary Hemorrhage From Dabigatran Overdose. American Journal of Kidney Diseases, 2013, 62, 591-594.	1.9	37
163	Reversal of novel oral anticoagulants in patients with major bleeding. Journal of Thrombosis and Thrombolysis, 2013, 35, 391-398.	2.1	78
164	Moving Toward a More Ideal Anticoagulant. Chest, 2013, 143, 1106-1116.	0.8	28
165	Removal of Dabigatran by Hemodialysis. American Journal of Kidney Diseases, 2013, 61, 487-489.	1.9	148
166	Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. European Journal of Clinical Pharmacology, 2013, 69, 1617-1633.	1.9	81
167	Glomerular Filtration Rate Equations Overestimate Creatinine Clearance in Older Individuals Enrolled in the Baltimore Longitudinal Study on Aging: Impact on Renal Drug Dosing. Pharmacotherapy, 2013, 33, 912-921.	2.6	122
168	Dabigatran, intracranial hemorrhage, and the neurosurgeon. Neurosurgical Focus, 2013, 34, E7.	2.3	14
169	Dabigatran: Is There a Role for Coagulation Assays in Guiding Therapy?. Annals of Pharmacotherapy, 2013, 47, 828-840.	1.9	8
170	Current State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors. Annals of Pharmacotherapy, 2013, 47, 841-855.	1.9	27
171	Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding: A Single Center Experience. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1533-1539.	4.5	91
172	Treatment of Bleeding Complications When Using Oral Anticoagulants for Prevention of Strokes. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 288-298.	0.9	24

#	ARTICLE	IF	CITATIONS
173	Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 37, 241-247.	1.3	38
174	Gastrointestinal disorders and dabigatran. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 9-16.	1.5	13
175	Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. <i>Internal Medicine Journal</i> , 2013, 43, 778-783.	0.8	11
176	Novel oral anticoagulants in gastroenterology practice. <i>Gastrointestinal Endoscopy</i> , 2013, 78, 227-239.	1.0	94
177	Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 53-63.	2.4	6
178	Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban. <i>Canadian Journal of Cardiology</i> , 2013, 29, S24-S33.	1.7	162
179	Developing a management plan for oral anticoagulant reversal. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, S21-S31.	1.0	19
180	Oral anticoagulants in the management of venous thromboembolism. <i>Nature Reviews Cardiology</i> , 2013, 10, 397-409.	13.7	14
181	Pharmacology of the new target-specific oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 133-140.	2.1	39
182	Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. <i>Clinical Research in Cardiology</i> , 2013, 102, 399-412.	3.3	179
183	Management of New Anticoagulants in the ICU. <i>ICU Director</i> , 2013, 4, 326-331.	0.2	0
184	Letter to the Editor: Anticoagulation. <i>Journal of Neurosurgery</i> , 2013, 118, 481-483.	1.6	1
185	Novel Oral Anticoagulants: A Review of the Literature and Considerations in Special Clinical Situations. <i>Hospital Practice (1995)</i> , 2013, 41, 8-18.	1.0	3
186	Fatal bleeding associated with dabigatran. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1651-1652.	1.0	4
187	Anticoagulation in the Perioperative Period. , 2013, , 673-687.		1
188	Dabigatran bleed risk with closed head injuries: are we prepared?. <i>Journal of Neurosurgery</i> , 2013, 119, 760-765.	1.6	39
189	Management of Hemorrhage Complicated by Novel Oral Anticoagulants in the Emergency Department. <i>American Journal of Therapeutics</i> , 2013, 20, 300-306.	0.9	18
190	Dabigatran: A Cause of Hematologic Emergency. <i>American Journal of the Medical Sciences</i> , 2013, 346, 190-193.	1.1	17

#	ARTICLE	IF	CITATIONS
191	Pathology Consultation on Monitoring Direct Thrombin Inhibitors and Overcoming Their Effects in Bleeding Patients. American Journal of Clinical Pathology, 2013, 140, 610-622.	0.7	18
192	Evolving practices in critical care and their influence on acute kidney injury. Current Opinion in Critical Care, 2013, 19, 1.	3.2	1
193	Haemodialysis before emergency surgery in a patient treated with dabigatran. British Journal of Anaesthesia, 2013, 111, 776-777.	3.4	19
194	Treatment of Dabigatran-Associated Bleeding. Journal of Pharmacy Practice, 2013, 26, 264-269.	1.0	46
195	Pituitary apoplexy during treatment with dabigatran. Neurology and Clinical Neuroscience, 2013, 1, 82-83.	0.4	6
196	Reversal of Dabigatran with Haemodialysis in a Patient Requiring Decompression for Cord Compression from an Epidural Abscess. Nephrology, 2013, 18, 580-582.	1.6	9
197	EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. European Heart Journal, 2013, 34, 2094-2106.	2.2	356
198	Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open, 2013, 3, e002686.	1.9	37
199	Pharmacogenetics of Oral Anticoagulants. , 2013, , 435-467.		0
200	Dabigatran and Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1591-1597.	4.5	32
201	Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting. Anesthesiology, 2013, 118, 1466-1474.	2.5	158
203	Reversing Dabigatran in Life-Threatening Bleeding Occurring During Cardiac Ablation With Factor Eight Inhibitor Bypassing Activity. Critical Care Medicine, 2013, 41, e42-e46.	0.9	92
204	Traumatic Intracranial Hemorrhage in Patients Taking Dabigatran. Neurosurgery, 2013, 73, E368-E374.	1.1	33
205	Gastrointestinal bleeding with the new oral anticoagulants “defining the issues and the management strategies. Thrombosis and Haemostasis, 2013, 110, 205-212.	3.4	155
206	Management of Bleeding Complications of Dabigatran. Journal of Hematology & Thromboembolic Diseases, 2013, 02, .	0.1	1
207	Dabigatran elimination: is haemodialysis effective?. Thrombosis and Haemostasis, 2013, 109, 580-581.	3.4	3
208	The practical management of bleedings during treatment with direct oral anticoagulants: the emergency reversal therapy. Italian Journal of Medicine, 2013, 7, 48.	0.3	2
209	Spinal Epidural Hematoma Following Epidural Steroid Injection in a Patient Treated with Dabigatran. JBJS Case Connector, 2013, 3, e64.	0.3	8

#	ARTICLE	IF	CITATIONS
210	The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients. Vascular Health and Risk Management, 2013, 9, 341.	2.3	16
211	Clinical trials update: recent and ongoing studies in anticoagulation for atrial fibrillation. Open Access Journal of Clinical Trials, 0, , 101.	1.5	0
212	Management of Severe Dabigatran-Related Hemorrhage: Case Report, Considerations for Management, and Recommendations. Canadian Journal of Hospital Pharmacy, 2014, 67, 43-7.	0.1	5
213	Immediate Treatment of the Anticoagulated Patient with Traumatic Intracranial Hemorrhage. , 2014, , .		0
214	Practical Management of Stroke Prevention in Patients with Atrial Fibrillation and Renal Impairment Receiving Newer Oral Anticoagulants: Focus on Rivaroxaban. Journal of General Practice (Los Angeles,) Tj ETQq0 0 0gBT /Overlock 10 Tf		
215	A practice tool for the new oral anticoagulants. Canadian Pharmacists Journal, 2014, 147, 25-32.	0.8	12
216	Translational Insights into Traumatic Brain Injury Occurring during Dabigatran or Warfarin Anticoagulation. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 870-875.	4.3	16
217	Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. Clinical Toxicology, 2014, 52, 283-287.	1.9	17
218	Stroke Prevention in Patients With Atrial Fibrillation and Renal Dysfunction. Stroke, 2014, 45, 2497-2505.	2.0	13
219	Prolonged Bleeding After Surgery. , 2014, , 151-160.		0
220	Direct oral anticoagulants: integration into clinical practice. Postgraduate Medical Journal, 2014, 90, 529-539.	1.8	15
221	The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emergency Medicine Journal, 2014, 31, 163-168.	1.0	64
222	Safety of new oral anticoagulants in high risk patients. BMJ, The, 2014, 348, g1861-g1861.	6.0	0
223	What is the role of hemodialysis for dabigatran-associated major bleeding?. Hematology American Society of Hematology Education Program, 2014, 2014, 514-517.	2.5	2
224	Direct Oral Anticoagulants. JACC: Cardiovascular Interventions, 2014, 7, 1333-1351.	2.9	81
225	A proposal for doseâ€adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. British Journal of Clinical Pharmacology, 2014, 78, 599-609.	2.4	25
226	Type A Aortic Dissection in a Patient on Dabigatran: Hemostasis Post Circulatory Arrest. Annals of Thoracic Surgery, 2014, 98, 2215-2216.	1.3	13
227	Dabigatran etexilate for venous thromboembolism: a safety evaluation. Expert Opinion on Drug Safety, 2014, 13, 639-647.	2.4	4

#	ARTICLE	IF	CITATIONS
228	Evaluation of Dabigatran Exposures Reported to Poison Control Centers. <i>Annals of Pharmacotherapy</i> , 2014, 48, 354-360.	1.9	15
229	Effects of Renal Impairment on the Pharmacokinetics of Morinidazole: Uptake Transporter-Mediated Renal Clearance of the Conjugated Metabolites. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4153-4161.	3.2	26
230	Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. <i>Thrombosis Journal</i> , 2014, 12, 25.	2.1	55
231	Management of Hemorrhage with the Target-Specific Oral Anticoagulants. <i>Hospital Practice (1995)</i> , 2014, 42, 75-83.	1.0	0
232	Emergent Reversal of Oral Anticoagulation. <i>AACN Advanced Critical Care</i> , 2014, 25, 5-12.	1.1	1
233	Emergency surgery and trauma in patients treated with the new oral anticoagulants. <i>Journal of Trauma and Acute Care Surgery</i> , 2014, 77, 486-494.	2.1	14
234	New oral anticoagulant agents – general features and outcomes in subsets of patients. <i>Thrombosis and Haemostasis</i> , 2014, 111, 575-582.	3.4	58
235	Switching between Oral Anticoagulants. <i>Hospital Practice (1995)</i> , 2014, 42, 68-74.	1.0	1
236	Evaluation of Dabigatran Utilization and Risk Among Hospitalized Patients. <i>Annals of Pharmacotherapy</i> , 2014, 48, 349-353.	1.9	4
237	Direct Oral Anticoagulants – Pharmacology, Drug Interactions, and Side Effects. <i>Seminars in Hematology</i> , 2014, 51, 89-97.	3.4	35
238	The Newer Anticoagulants in Thrombosis Control in Cancer Patients. <i>Seminars in Oncology</i> , 2014, 41, 339-345.	2.2	4
239	<i>Enterococcus faecalis</i> bacteremia and mitral valve endocarditis under dabigatran for stroke prevention. <i>International Journal of Cardiology</i> , 2014, 174, 836-838.	1.7	4
240	The pharmacology of novel oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 217-233.	2.1	54
242	Dabigatran anticoagulation and Stanford type A aortic dissection: lethal coincidence. <i>Acta Anaesthesiologica Scandinavica</i> , 2014, 58, 630-637.	1.6	19
243	New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications. <i>Acta Anaesthesiologica Scandinavica</i> , 2014, 58, 651-659.	1.6	25
244	Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants. <i>American Journal of Emergency Medicine</i> , 2014, 32, 375-382.	1.6	25
245	Novel Oral Anticoagulants: A Focused Review for Stroke Physicians. <i>International Journal of Stroke</i> , 2014, 9, 71-78.	5.9	12
246	Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. <i>Blood Reviews</i> , 2014, 28, 1-8.	5.7	29

#	ARTICLE	IF	CITATIONS
247	New Oral Anticoagulants and the Cancer Patient. <i>Oncologist</i> , 2014, 19, 82-93.	3.7	180
248	Protocol in managing oral surgical patients taking dabigatran. <i>Australian Dental Journal</i> , 2014, 59, 296-301.	1.5	52
249	Measurement of nonâ€œCoumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. <i>British Journal of Haematology</i> , 2014, 166, 830-841.	2.5	142
250	New Oral Anticoagulants in the Management of Venous Thromboembolism: A Major Advance?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2014, 48, 487-488.	1.5	2
252	Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of dabigatran etexilate, intermediate metabolite and dabigatran in 50Î¼L rat plasma and its application to pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 973, 110-119.	2.3	19
253	Measurement of Dabigatran in Standardly Used Clinical Assays, Whole Blood Viscoelastic Coagulation, and Thrombin Generation Assays. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 479-501.	1.4	29
254	Periprocedural Management of Patients on Anticoagulants. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 595-611.	1.4	5
255	Dabigatran Etexilate: A Review of Its Use in the Treatment of Acute Venous Thromboembolism and Prevention of Venous Thromboembolism Recurrence. <i>Drugs</i> , 2014, 74, 1785-1800.	10.9	23
256	What is the Role of Renal Replacement Therapy in the Setting of Dabigatran Toxicity?. <i>Seminars in Dialysis</i> , 2014, 27, 223-226.	1.3	2
257	The epidemic of pre-injury oral antiplatelet and anticoagulant use. <i>European Journal of Trauma and Emergency Surgery</i> , 2014, 40, 657-669.	1.7	13
258	The effect of stroke and other components in Xing-Nao-Jing on the pharmacokinetics of geniposide. <i>Journal of Ethnopharmacology</i> , 2014, 152, 302-307.	4.1	22
259	Benefitâ€œRisk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation. <i>Drug Safety</i> , 2014, 37, 295-307.	3.2	3
260	Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C. <i>Drugs in R and D</i> , 2014, 14, 113-123.	2.2	38
261	The role of prothrombin complex concentrates in reversal of target specific anticoagulants. <i>Thrombosis Journal</i> , 2014, 12, 8.	2.1	47
262	On the monitoring of dabigatran treatment in â€œreal lifeâ€œpatients with atrial fibrillation. <i>Thrombosis Research</i> , 2014, 134, 783-789.	1.7	47
263	New oral anticoagulants: a practical guide on prescription, laboratory testing and periâ€œprocedural/bleeding management. <i>Internal Medicine Journal</i> , 2014, 44, 525-536.	0.8	129
264	Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 118-135.	1.5	30
265	Direct Oral Anticoagulants and Bleeding Risk (in Comparison to Vitamin K Antagonists and Heparins), and the Treatment of Bleeding. <i>Seminars in Hematology</i> , 2014, 51, 102-111.	3.4	17

#	ARTICLE	IF	CITATIONS
266	An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 901-909.	2.0	24
267	Learning More From the Dabigatran Concentrations in the RE-LY Study. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2746-2747.	2.8	3
268	An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system. <i>American Journal of Emergency Medicine</i> , 2014, 32, 1077-1084.	1.6	28
269	Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 630-638.	2.4	16
270	Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error. <i>Investigational New Drugs</i> , 2014, 32, 913-927.	2.6	5
271	Potential antidotes for reversal of old and new oral anticoagulants. <i>Thrombosis Research</i> , 2014, 133, S158-S166.	1.7	37
272	Novel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-analysis of Randomized Trials. <i>Canadian Journal of Cardiology</i> , 2014, 30, 888-897.	1.7	65
273	How I treat target-specific oral anticoagulant-associated bleeding. <i>Blood</i> , 2014, 123, 1152-1158.	1.4	108
274	New Oral Anticoagulants. <i>ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology</i> , 2014, 22, .	0.0	0
275	Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation. <i>Journal of Arrhythmia</i> , 2015, 31, 183-188.	1.2	11
276	Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications. <i>Regional Anesthesia and Pain Medicine</i> , 2015, 40, 182-212.	2.3	248
277	Prescribing patterns of target-specific oral anticoagulants. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 767-771.	1.0	3
278	Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran. <i>British Journal of Haematology</i> , 2015, 169, 603-604.	2.5	20
279	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. <i>Thrombosis and Haemostasis</i> , 2015, 113, 625-632.	3.4	201
280	A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. <i>Thrombosis Journal</i> , 2015, 13, 29.	2.1	1
281	The Real-World Treatment of Hemorrhages Associated With Dabigatran and Rivaroxaban. <i>Critical Pathways in Cardiology</i> , 2015, 14, 53-61.	0.5	15
282	Analysis of the influence of dabigatran on coagulation factors and inhibitors. <i>International Journal of Laboratory Hematology</i> , 2015, 37, 225-230.	1.3	9
283	Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach. <i>Thrombosis and Haemostasis</i> , 2015, 114, 660-669.	3.4	9

#	ARTICLE	IF	CITATIONS
284	Considerations for Systemic Anticoagulation in <scp>ESRD</scp>. Seminars in Dialysis, 2015, 28, 354-362.	1.3	1
285	Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. Journal of Thrombosis and Haemostasis, 2015, 13, 1790-1798.	3.8	60
286	Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery. Dermatologic Surgery, 2015, 41, 784-793.	0.8	30
287	Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism. Journal of Blood Medicine, 2015, 6, 177.	1.7	2
288	Current and emerging strategies in the management of venous thromboembolism: benefit–risk assessment of dabigatran. Vascular Health and Risk Management, 2015, 11, 271.	2.3	7
289	Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clinical Interventions in Aging, 2015, 10, 1431.	2.9	20
290	Gastrointestinal Bleeding with Dabigatran, a Comparative Study with Warfarin: A Multicenter Experience. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2015, 65, 205.	0.4	7
291	Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thrombosis and Haemostasis, 2015, 114, 1113-1126.	3.4	59
293	Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age. International Journal of Medical Sciences, 2015, 12, 312-321.	2.5	25
294	Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management. BioMed Research International, 2015, 2015, 1-8.	1.9	9
295	Anticoagulation in patients with impaired renal function and with haemodialysis. Hamostaseologie, 2015, 35, 77-83.	1.9	13
296	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. Drugs, 2015, 75, 979-998.	10.9	10
297	Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2015, 15, 323-335.	2.2	9
298	Oral anticoagulation: a critique of recent advances and controversies. Trends in Pharmacological Sciences, 2015, 36, 153-163.	8.7	70
299	Management of oral anticoagulation in the surgical patient. ANZ Journal of Surgery, 2015, 85, 620-625.	0.7	3
300	New Insights into Nonvitamin K Antagonist Oral Anticoagulants' Reversal of Intracerebral Hemorrhage. Frontiers of Neurology and Neuroscience, 2016, 37, 93-106.	2.8	5
301	Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran. Journal of Pharmacy Practice, 2015, 28, 548-554.	1.0	8
302	Rivaroxaban and intracranial haemorrhage after mild traumatic brain injury: A dangerous combination?. Clinical Neurology and Neurosurgery, 2015, 136, 73-78.	1.4	36

#	ARTICLE	IF	CITATIONS
303	Ultrasound-Guided Fine-Needle Aspiration Biopsy of Thyroid Nodules in Patients Taking Novel Oral Anticoagulants. <i>Thyroid</i> , 2015, 25, 373-376.	4.5	23
304	Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. <i>Clinical Toxicology</i> , 2015, 53, 156-163.	1.9	29
305	New oral anti-coagulants: Implications for neurosurgery. <i>British Journal of Neurosurgery</i> , 2015, 29, 182-188.	0.8	2
306	Dabigatran-Associated Intracranial Hemorrhage. <i>Neurohospitalist</i> , The, 2015, 5, 234-244.	0.8	12
307	The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: Rationale and a summary of the available evidence from phase 3 clinical trials. <i>American Heart Journal</i> , 2015, 169, 315-322.	2.7	9
308	Management of perioperative anti-thrombotic therapy. <i>Anaesthesia</i> , 2015, 70, 58.	3.8	44
309	Real-world variability in dabigatran levels in patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 353-359.	3.8	62
310	Monitoring and reversal strategies for new oral anticoagulants. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 95-103.	1.5	33
311	Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 395-402.	2.1	66
312	Farmacología clínica comparada de los anticoagulantes orales: AVK y nuevos anticoagulantes. <i>EMC - Tratado De Medicina</i> , 2015, 19, 1-5.	0.0	0
313	Management of dabigatran-induced bleeding with continuous venovenous hemodialysis. <i>International Journal of Hematology</i> , 2015, 101, 594-597.	1.6	10
314	Evaluation of Dosing Practices of Rivaroxaban and Dabigatran. <i>Journal of Pharmacy Technology</i> , 2015, 31, 149-154.	1.0	1
315	Enhanced Elimination of Dabigatran Through Extracorporeal Methods. <i>Journal of Medical Toxicology</i> , 2015, 11, 85-95.	1.5	13
316	Target-specific oral anticoagulants and the hospitalist. <i>Hospital Practice (1995)</i> , 2015, 43, 1-12.	1.0	1
317	Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 199-201.	2.9	8
318	Dosing of Target-Specific Oral Anticoagulants in Special Populations. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1031-1045.	1.9	16
319	Antidotes for Novel Oral Anticoagulants. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1736-1745.	2.4	114
320	Patients' Serum and Urine as Easily Accessible Samples for the Measurement of Non-Vitamin K Antagonist Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 228-236.	2.7	22

#	ARTICLE	IF	CITATIONS
321	Peri-procedural management of patients taking oral anticoagulants. BMJ, The, 2015, 351, h2391.	6.0	37
322	New Oral Anticoagulants. Medical Clinics of North America, 2015, 99, 759-780.	2.5	5
325	Use of 4-factor prothrombin complex concentrate in the treatment of a gastrointestinal hemorrhage complicated by dabigatran. International Journal of Emergency Medicine, 2015, 8, 10.	1.6	7
326	Management of anticoagulation in patients with acute gastrointestinal bleeding. Digestive and Liver Disease, 2015, 47, 621-627.	0.9	58
327	Quantification of dabigatran and indirect quantification of dabigatran acylglucuronides in human plasma by LC-MS/MS. Bioanalysis, 2015, 7, 957-966.	1.5	11
328	Perioperative Management of Dabigatran. Circulation, 2015, 132, 167-173.	1.6	133
329	Perioperatively acquired disorders of coagulation. Current Opinion in Anaesthesiology, 2015, 28, 113-122.	2.0	24
330	Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 457-464.	2.0	2
331	Dabigatran for the prevention and treatment of thromboembolic disorders. Expert Review of Cardiovascular Therapy, 2015, 13, 529-540.	1.5	6
332	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clinical Research in Cardiology, 2015, 104, 418-429.	3.3	87
333	Perioperative Management of Antithrombotic Therapy in Common Otolaryngologic Surgical Procedures. Otolaryngology - Head and Neck Surgery, 2015, 153, 493-503.	1.9	26
334	Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Critical Care, 2015, 19, 203.	5.8	77
337	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17, 1467-1507.	1.7	951
338	Dabigatran for the treatment of venous thromboembolism. Expert Review of Hematology, 2015, 8, 413-425.	2.2	4
339	Reversal of Anticoagulant Effects in Patients with Intracerebral Hemorrhage. Current Neurology and Neuroscience Reports, 2015, 15, 504.	4.2	7
341	A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage. Journal of Intensive Care Medicine, 2015, 30, 462-472.	2.8	20
342	The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants. Current Medical Research and Opinion, 2015, 31, 197-210.	1.9	11
343	Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. Thrombosis and Haemostasis, 2016, 115, 271-284.	3.4	49

#	ARTICLE	IF	CITATIONS
344	Atrial Fibrillation Management in Older Heart Failure Patients: A Complex Clinical Problem. Heart International, 2016, 11, heartint.500023.	1.4	10
345	Dabigatran treatment simulation in patients undergoing maintenance haemodialysis. Thrombosis and Haemostasis, 2016, 115, 562-569.	3.4	9
346	Direct Oral Anticoagulants in Emergency Trauma Admissions. Deutsches Ärztblatt International, 2016, 113, 575-82.	0.9	35
347	Use of Continuous Renal Replacement Therapy for Removal of Dabigatran in a Patient in Need of Emergent Surgery. Case Reports in Critical Care, 2016, 2016, 1-5.	0.4	4
348	Uso de los anticoagulantes orales directos en la pr�ctica cl�nica. Revista Facultad De Medicina, 2016, 64, 295.	0.2	1
349	Lumbar puncture in patients using anticoagulants and antiplatelet agents. Archivos De Neuro-Psiquiatria, 2016, 74, 679-686.	0.8	13
350	Recent Advances in the Pharmacological Management of Atrial Fibrillation. American Journal of Therapeutics, 2016, 23, e118-e138.	0.9	2
351	Effects of renal impairment on the pharmacokinetics of orally administered deferiprone. British Journal of Clinical Pharmacology, 2016, 82, 994-1001.	2.4	10
352	Perioperative Management of Anticoagulation��Review of Latest Evidence. American Journal of Therapeutics, 2016, 23, e474-e484.	0.9	8
353	Reversal of Target-Specific Oral Anticoagulants. , 2016, , 47-54.		0
355	Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin. Journal of Clinical Pharmacology, 2016, 56, 203-212.	2.0	13
356	Enhanced elimination of dabigatran: Identifying the appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysis��A simulation analysis. Journal of Clinical Pharmacology, 2016, 56, 597-608.	2.0	7
357	Management of direct oral anticoagulants-associated bleeding in the trauma patient. Current Opinion in Anaesthesiology, 2016, 29, 220-228.	2.0	16
358	When to stop, how to reverse, and when to restart antithrombotic drugs periendoscopically in nonvariceal upper gastrointestinal bleeding. Techniques in Gastrointestinal Endoscopy, 2016, 18, 177-186.	0.3	0
360	Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data. International Journal of Cardiology, 2016, 214, 292-298.	1.7	79
361	Observational study of dabigatran etexilate 150 mg in patients with moderate renal impairment undergoing elective total hip or knee replacement. Thrombosis Research, 2016, 143, 103-110.	1.7	4
362	Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants. American Journal of Health-System Pharmacy, 2016, 73, s14-s26.	1.0	15
363	Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants. Air Medical Journal, 2016, 35, 148-155.	0.6	16

#	ARTICLE	IF	CITATIONS
365	Evolving Treatments for Arterial and Venous Thrombosis. <i>Circulation Research</i> , 2016, 118, 1409-1424.	4.5	96
367	Renal Replacement Therapy in the Critically Ill Surgical Patient. , 2016, , 159-168.		0
368	Clinical practice guideline on thromboprophylaxis and management of anticoagulant and antiplatelet drugs in neurosurgical and neurocritical patients. <i>Revista Española De Anestesiología Y Reanimación</i> (English Edition), 2016, 63, 406-418.	0.1	0
369	Estimated glomerular filtration rate calculated using different creatinine and cystatin based formulas in prediction of trough plasma Dabigatran concentration. <i>Clinica Chimica Acta</i> , 2016, 463, 22-26.	1.1	0
370	Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 1182-1190.	2.1	5
371	The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 285-300.	2.4	40
372	Hemodialysis for removal of dabigatran in a patient with gastric hemorrhage. <i>Acute Medicine & Surgery</i> , 2016, 3, 132-134.	1.2	3
373	Major bleeding complications in patients treated with direct oral anticoagulants: One-year observational study in a Paris Hospital. <i>Current Research in Translational Medicine</i> , 2016, 64, 129-133.	1.8	2
374	Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. <i>Circulation</i> , 2016, 134, 248-261.	1.6	98
376	Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review. <i>Health Services Insights</i> , 2016, 9s1, HSI.S40701.	1.3	25
377	Glomerular filtration rate assessed by using creatinine and cystatin in patients treated with dabigatran. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2016, 12, 243-248.	0.4	1
378	New anticoagulants in cancer patient treatments. <i>Anti-Cancer Drugs</i> , 2016, 27, 832-838.	1.4	2
379	Use of Extracorporeal Techniques in the Removal of Dabigatran. <i>American Journal of Therapeutics</i> , 2016, 23, e485-e488.	0.9	0
380	An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. <i>Thrombosis Research</i> , 2016, 144, 158-164.	1.7	4
381	Drug Treatment of Venous Thromboembolism in the Elderly. <i>Drugs and Aging</i> , 2016, 33, 475-490.	2.7	6
382	Clinical follow-up of atrial-fibrillation patients treated with novel oral anti-coagulants: A multi-disciplinary consensus from the Apulia section of the Italian Association of Hospital Cardiologists (ANMCO). <i>International Journal of Cardiology</i> , 2016, 202, 265-272.	1.7	3
383	Idarucizumab for dabigatran overdose. <i>Clinical Toxicology</i> , 2016, 54, 644-646.	1.9	30
384	Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting. <i>Thrombosis Journal</i> , 2016, 14, 10.	2.1	11

#	ARTICLE	IF	CITATIONS
385	Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. Journal of the American College of Cardiology, 2016, 67, 2888-2899.	2.8	171
386	Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 20-26.	2.0	2
387	Pharmacological thromboprophylaxis and total hip or knee replacement. British Journal of Nursing, 2016, 25, 45-53.	0.7	4
388	Pharmacology of anticoagulants used in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 15-31.	2.1	108
389	The Complex Role of Anticoagulation in Cirrhosis: An Updated Review of Where We Are and Where We Are Going. Digestion, 2016, 93, 149-159.	2.3	51
390	Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure. Chest, 2016, 149, 1516-1524.	0.8	43
391	Target-specific Oral Anticoagulants in the Emergency Department. Journal of Emergency Medicine, 2016, 50, 246-257.	0.7	3
392	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. Thrombosis Research, 2016, 140, 81-88.	1.7	14
393	Management of Venous Thromboembolism. Annals of Pharmacotherapy, 2016, 50, 486-501.	1.9	21
394	Novel oral anticoagulants in plastic surgery. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2016, 69, 585-593.	1.0	8
395	Guía de práctica clínica sobre tromboprofilaxis y manejo de los fármacos anticoagulantes y antiagregantes en pacientes neuroquirúrgicos y neurocríticos. Revista Española De Anestesiología Y Reanimación, 2016, 63, 406-418.	0.3	2
396	Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage. Neurocritical Care, 2016, 24, 6-46.	2.4	550
397	Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician. Journal of Cardiothoracic and Vascular Anesthesia, 2016, 30, 823-830.	1.3	11
398	The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use. Expert Review of Cardiovascular Therapy, 2016, 14, 163-176.	1.5	8
399	Assessment of the Effects of Antithrombotic Drugs. , 2016, , 173-192.		0
400	How to effectively manage the event of bleeding complications when using anticoagulants. Expert Review of Hematology, 2016, 9, 37-50.	2.2	13
401	The effect of ultrafiltration with cardiopulmonary bypass on the removal of dabigatran from the circulation of adult pigs. Perfusion (United Kingdom), 2016, 31, 424-430.	1.0	4
402	Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures. International Journal of Cardiology, 2016, 202, 578-585.	1.7	34

#	ARTICLE	IF	CITATIONS
403	Coagulation assessment with the new generation of oral anticoagulants. Emergency Medicine Journal, 2016, 33, 423-430.	1.0	58
404	Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace, 2016, 18, 955-964.	1.7	62
405	Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study. Clinical Pharmacokinetics, 2017, 56, 41-54.	3.5	70
406	Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism. Pharmacological Research, 2017, 118, 33-42.	7.1	31
407	The Neurostimulation Appropriateness Consensus Committee (NACC): Recommendations on Bleeding and Coagulation Management in Neurostimulation Devices. Neuromodulation, 2017, 20, 51-62.	0.8	66
408	Risk of Gastrointestinal Bleeding Among Dabigatran Users – A Self Controlled Case Series Analysis. Scientific Reports, 2017, 7, 40120.	3.3	1
409	Perioperative Management of Anticoagulation. Neurosurgery Clinics of North America, 2017, 28, 287-295.	1.7	12
410	Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity. International Urology and Nephrology, 2017, 49, 1401-1407.	1.4	28
411	Dabigatran Etxilate: A Review in Nonvalvular Atrial Fibrillation. Drugs, 2017, 77, 331-344.	10.9	19
413	Real-world stroke prevention strategies in nonvalvular atrial fibrillation in patients with renal impairment. European Journal of Clinical Investigation, 2017, 47, 428-438.	3.4	5
414	Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients. Circulation: Heart Failure, 2017, 10, .	3.9	64
415	Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. Thrombosis Research, 2017, 155, 38-47.	1.7	27
416	Pharmacokinetic and pharmacodynamic alterations in older people with dementia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 651-668.	3.3	55
417	Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. International Journal of Hematology, 2017, 105, 532-535.	1.6	7
418	Dabigatran in nonvalvular atrial fibrillation. Journal of Cardiovascular Medicine, 2017, 18, 467-477.	1.5	7
419	Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure. European Journal of Anaesthesiology, 2017, 34, 400-402.	1.7	12
420	Novel (Oral) Anticoagulant Challenges in Surgery. Seminars in Thrombosis and Hemostasis, 2017, 43, 706-715.	2.7	5
421	Bleeding Complications and Management on anticoagulant therapy. Seminars in Thrombosis and Hemostasis, 2017, 43, 886-892.	2.7	10

#	ARTICLE	IF	CITATIONS
422	Proposal for the Rapid Reversal of Coagulopathy in Patients with Nonoperative Head Injuries on Anticoagulants and/or Antiplatelet Agents: A Case Study and Literature Review. <i>Neurosurgery</i> , 2017, 81, 899-909.	1.1	10
423	Novel Anticoagulant Agents in the Perioperative Setting. <i>Anesthesiology Clinics</i> , 2017, 35, 305-313.	1.4	9
424	Direct Oral Anticoagulants: An Overview for the Interventional Radiologist. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 321-330.	2.0	5
425	Idarucizumab since FDA approval: Use in the real-world. <i>American Heart Journal</i> , 2017, 193, 93-94.	2.7	6
426	Common Pharmacologic Issues. , 2017, , 405-414.		0
427	Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. <i>Internal and Emergency Medicine</i> , 2017, 12, 1101-1108.	2.0	14
428	Dabigatran-Induced Massive Spontaneous Hemothorax. <i>Drug Safety - Case Reports</i> , 2017, 4, 12.	0.9	6
430	Does Secretory Clearance Follow Glomerular Filtration Rate in Chronic Kidney Diseases? Reconsidering the Intact Nephron Hypothesis. <i>Clinical and Translational Science</i> , 2017, 10, 395-403.	3.1	32
431	Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease. <i>CardioRenal Medicine</i> , 2017, 7, 207-217.	1.9	13
432	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3042-3067.	2.8	285
433	Cardiac Evaluation and Monitoring of Patients Undergoing Noncardiac Surgery. <i>Health Services Insights</i> , 2017, 10, 117863291668607.	1.3	7
435	Indications and Methods of Anticoagulation Reversal. <i>Surgical Clinics of North America</i> , 2017, 97, 1291-1305.	1.5	12
436	Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism. <i>American Journal of Medicine</i> , 2017, 130, 1137-1143.	1.5	7
437	Monitoring and Reversal of Oral Anticoagulation in Hospitalized Patients. <i>Hospital Medicine Clinics</i> , 2017, 6, 330-347.	0.2	0
438	Novel oral anticoagulants: beyond the myth. <i>Current Medical Research and Opinion</i> , 2017, 33, 125-127.	1.9	0
439	Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. <i>Clinical Cardiology</i> , 2017, 40, 46-52.	1.8	25
440	Direct oral anticoagulant considerations in solid organ transplantation: A review. <i>Clinical Transplantation</i> , 2017, 31, e12873.	1.6	41
441	ANMCO Position Paper: the use of non-vitamin K dependent new oral anticoagulant(s) in pulmonary embolism therapy and prevention. <i>European Heart Journal Supplements</i> , 2017, 19, D293-D308.	0.1	4

#	ARTICLE	IF	CITATIONS
442	The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2415-2424.	3.4	62
443	Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2045-2052.	3.4	36
444	Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition). <i>Regional Anesthesia and Pain Medicine</i> , 2017, 43, 1.	2.3	117
445	Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. <i>Hamostaseologie</i> , 2017, 37, 241-255.	1.9	12
446	Pharmacological profile of non-vitamin K antagonist oral anticoagulants. <i>African Journal of Pharmacy and Pharmacology</i> , 2017, 11, 125-136.	0.3	4
447	Update on Direct Oral AntiCoagulants (DOACs). <i>Hamostaseologie</i> , 2017, 37, 267-275.	1.9	9
448	Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. <i>International Journal of Nephrology and Renovascular Disease</i> , 2017, Volume 10, 135-143.	1.8	90
449	Reversal of direct oral anticoagulants. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 287-292.	2.3	27
450	Non-vitamin-K-dependent Oral Anticoagulants in End-stage Renal Disease Patients with Non-valvular Atrial Fibrillation: An Impossible Wedding?. <i>Giornale De Tecniche Nefrologiche & Dialitiche</i> , 2017, 29, 117-126.	0.1	0
451	Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 447-454.	2.0	11
452	Management of oral antiplatelet agents and anticoagulation therapy before bronchoscopy. <i>Journal of Thoracic Disease</i> , 2017, 9, S1022-S1033.	1.4	19
453	Is anticoagulating haemodialysis patients with non-valvular atrial fibrillation too risky?. <i>British Journal of Haematology</i> , 2018, 181, 725-736.	2.5	9
455	Transitioning Between Anticoagulants. , 2018, , 133-150.		0
456	Fatal Adverse Event with Dabigatran in Elderly Patient with Reduced Kidney Function. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 221-226.	2.5	3
457	Management of the Trauma Patient on Direct Oral Anticoagulants. <i>Current Anesthesiology Reports</i> , 2018, 8, 107-118.	2.0	0
458	Direct Oral Anticoagulants in End-Stage Renal Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 353-363.	2.7	16
460	Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 399-406.	2.0	11
461	Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. <i>Nature Reviews Nephrology</i> , 2018, 14, 337-351.	9.6	89

#	ARTICLE	IF	CITATIONS
462	Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy. Regional Anesthesia and Pain Medicine, 2018, 43, 263-309.	2.3	596
463	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal, 2018, 39, 1330-1393.	2.2	1,576
464	Dabigatran Reversal in a Patient With End-Stage Liver Disease And Acute Kidney Injury. American Journal of Kidney Diseases, 2018, 71, 137-141.	1.9	15
465	Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs. Clinical Pharmacokinetics, 2018, 57, 505-514.	3.5	3
466	Real-Life Peak and Trough Dabigatran Plasma Measurements Over Time in Hospitalized Geriatric Patients with Atrial Fibrillation. Journal of Nutrition, Health and Aging, 2018, 22, 165-173.	3.3	13
467	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. American Journal of Cardiology, 2018, 121, 131-140.	1.6	15
468	Major publications in the critical care pharmacotherapy literature: January-December 2016. Journal of Critical Care, 2018, 43, 327-339.	2.2	6
469	Interventional Pain Procedures in Patients on Anticoagulants. , 2018, , 805-812.e2.		1
471	Diagnosis and Treatment of Pulmonary Embolism in Challenging Populations. Hamostaseologie, 2018, 38, 87-97.	1.9	2
472	Hypercoagulability in End-stage Liver Disease: Review of Epidemiology, Etiology, and Management. Transplantation Direct, 2018, 4, e403.	1.6	27
474	Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion. Journal of the American Heart Association, 2018, 7, e010854.	3.7	7
475	International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery. Anaesthesia, 2018, 73, 1535-1545.	3.8	49
476	Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time. Thrombosis Research, 2018, 171, 62-67.	1.7	4
477	Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges. Korean Circulation Journal, 2018, 48, 873.	1.9	10
478	Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants. Mayo Clinic Proceedings, 2018, 93, 1503-1519.	3.0	11
479	Interruption and Reversal of Direct Oral Anticoagulants in Preprocedural and Acute Settings. Journal of the American Board of Family Medicine, 2018, 31, 817-827.	1.5	2
480	Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios. IJC Heart and Vasculature, 2018, 20, 56-62.	1.1	34
481	Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?. International Urology and Nephrology, 2018, 50, 1633-1642.	1.4	3

#	ARTICLE	IF	CITATIONS
482	The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients. Expert Review of Hematology, 2018, 11, 487-494.	2.2	1
483	Nonvitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Renal Dysfunction. Revista Espanola De Cardiologia (English Ed), 2018, 71, 847-855.	0.6	4
484	Managing Antithrombotic Agents in the Setting of Acute Gastrointestinal Bleeding. Gastrointestinal Endoscopy Clinics of North America, 2018, 28, 351-361.	1.4	6
485	Clinical Pharmacokinetics in Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1085-1095.	4.5	142
486	Protein and Tissue Binding. , 2018, , 371-399.		2
487	Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacological Research, 2018, 135, 60-79.	7.1	81
488	A survey of reasons for continuing warfarin therapy in the era of direct oral anticoagulants in Japanese patients with atrial fibrillation: the SELECT study. Patient Preference and Adherence, 2018, Volume 12, 135-143.	1.8	17
489	When to Resume Direct Oral Anticoagulants Following Gastrointestinal Bleeding. Clinical Gastroenterology and Hepatology, 2018, 16, 1870-1871.	4.4	0
490	Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab. British Journal of Anaesthesia, 2018, 121, 505-508.	3.4	29
491	Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 278-287.	4.5	61
492	Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 499-508.	2.0	2
493	Direct-Acting Oral Anticoagulants in Critically Ill Patients. Chest, 2019, 156, 604-618.	0.8	11
494	Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins. Molecular Pharmaceutics, 2019, 16, 4065-4076.	4.6	10
495	Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update. Medicines (Basel), 2019, 16, 1078-1084.	1.4	31
496	Assessing Potential Drug–Drug Interactions Between Dabigatran Etxilate and a P-glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 118-126.	2.5	17
497	Optimizing Anticoagulation in Older Patients with Nonvalvular Atrial Fibrillation. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	0
498	Reversing Direct Oral Anticoagulants in Acute Intracranial Hemorrhage. Critical Care Nurse, 2019, 39, e1-e8.	1.0	1
499	A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etxilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients. Clinical Pharmacokinetics, 2019, 58, 1577-1593.	3.5	16

#	ARTICLE	IF	CITATIONS
500	Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1319-1328.	3.8	5
501	The acceptability of a direct oral anticoagulant monitoring regimen among patients with atrial fibrillation: a pilot study. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 682-686.	2.1	3
502	Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 42-46.	1.0	8
503	Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 1-12.	1.6	49
504	Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1154-1160.	1.7	16
505	Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. <i>Ageing Research Reviews</i> , 2019, 49, 115-124.	10.9	34
506	Pharmacology of Oral Anticoagulants. , 2019, , 11-34.		2
507	Management of Bleeding Associated With Anticoagulation. , 2019, , 91-103.		0
508	Hematologic Interventions for Acute Central Nervous System Disease. , 2019, , 778-801.		0
509	Ten things ICU specialists need to know about direct oral anticoagulants (DOACs). <i>Intensive Care Medicine</i> , 2019, 45, 89-92.	8.2	1
510	Thrombin-induced platelet aggregation - effect of dabigatran using automated platelet aggregometry. <i>Platelets</i> , 2020, 31, 360-364.	2.3	7
511	Stroke Prophylaxis in Patients with Atrial Fibrillation and End-Stage Renal Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 123.	2.4	11
512	Perioperative Management of Direct Oral Anticoagulants in Intracranial Surgery. <i>Journal of Neurosurgical Anesthesiology</i> , 2020, 32, 300-306.	1.2	3
513	Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. <i>Journal of the American Heart Association</i> , 2020, 9, e017316.	3.7	18
514	Refractory Dabigatran-Induced Hemorrhage Despite Multiple Idarucizumab Administration and Renal Replacement Therapy. <i>Journal of Pharmacy Practice</i> , 2022, 35, 302-307.	1.0	2
515	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2020, 76, 594-622.	2.8	187
516	Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study. <i>BMC Medicine</i> , 2020, 18, 254.	5.5	23
517	Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2020, 19, 178-186.	0.5	1

#	ARTICLE	IF	CITATIONS
518	Response to: Time frame for withholding direct thrombin inhibitor therapy before neurosurgery. Clinical Neurology and Neurosurgery, 2020, 197, 106224.	1.4	0
519	Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 151-156.	2.2	8
520	Drug-Drug Interactions with Direct Oral Anticoagulants. Clinical Pharmacokinetics, 2020, 59, 967-980.	3.5	76
521	Interventional Algorithm in Gastrointestinal Bleeding: An Expert Consensus Multimodal Approach Based on a Multidisciplinary Team. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962093194.	1.7	8
522	Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses. BMC Cardiovascular Disorders, 2020, 20, 42.	1.7	29
523	Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis. Clinical Toxicology, 2020, 58, 789-800.	1.9	7
524	The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight. Cardiovascular Drugs and Therapy, 2021, 35, 505-519.	2.6	14
525	Dabigatran overload in acute kidney injury: haemodialysis or idarucizumab? A case report and proposal for a decisional algorithm. CKJ: Clinical Kidney Journal, 2021, 14, 712-714.	2.9	5
526	Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment. Clinical Pharmacology and Therapeutics, 2021, 109, 193-200.	4.7	7
527	Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function. Clinical Pharmacology and Therapeutics, 2021, 109, 1593-1605.	4.7	7
528	Evaluation of Extended-Interval Dabigatran Dosing in Older Patients With Non-Valvular Atrial Fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 359-364.	2.0	1
529	Review of Medical Therapies for the Management of Pulmonary Embolism. Medicina (Lithuania), 2021, 57, 110.	2.0	9
530	Dabigatran Reversal With Idarucizumab in 2 Patients With Portal Vein Thrombosis Undergoing Orthotopic Liver Transplantation. Seminars in Cardiothoracic and Vascular Anesthesia, 2021, 25, 200-207.	1.0	4
531	Direct Oral Anticoagulants in the Treatment of Venous Thromboembolism: Use in Patients with Advanced Renal Impairment, Obesity, or Other Weight-Related Special Populations. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 233-249.	2.1	2
532	Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction. Rational Pharmacotherapy in Cardiology, 2021, 17, 62-72.	0.8	0
533	Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis. American Journal of Kidney Diseases, 2021, 78, 678-689.e1.	1.9	24
534	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 2021, 23, 1612-1676.	1.7	494
535	Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection. Frontiers in Pharmacology, 2021, 12, 679431.	3.5	0

#	ARTICLE	IF	CITATIONS
536	Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis Following Robot-assisted Radical Cystectomy: A Retrospective Feasibility Study at a Single Academic Medical Center. <i>Urology</i> , 2021, 156, 154-162.	1.0	4
537	A Matched Control Analysis on the Effects of Alcohol Use Disorder After Primary Total Knee Arthroplasty in Medicare Patients. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2021, 29, e593-e600.	2.5	7
538	Clinical protocols for oral anticoagulant reversal during high risk of bleeding for emergency surgical and nonsurgical settings: a narrative review. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2021, 71, 429-442.	0.4	2
539	Optimal Management of Anticoagulation Therapy in Asian Patients With Atrial Fibrillation. <i>Circulation Journal</i> , 2021, 85, 1245-1253.	1.6	5
540	Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 974-984.	1.6	3
541	Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1091-1102.	3.3	1
542	Reversal of direct oral anticoagulants in adult hip fracture patients. A systematic review and meta-analysis. <i>Injury</i> , 2021, 52, 3206-3216.	1.7	3
543	Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. <i>Kidney International</i> , 2021, 100, 1199-1207.	5.2	23
544	Development and validation of LC-MS/MS method for simultaneous determination of dabigatran etexilate and its active metabolites in human plasma, and its application in a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 203, 114220.	2.8	5
545	Considerations and Guidelines for Use of Anticoagulants and Antithrombotics in Patients Undergoing Interventional Pain Management. , 2021, , 443-454.		0
547	Antithrombotika und Antihämorrhagika. , 2012, , 425-445.		2
548	Antithrombotika und Antihämorrhagika. , 2013, , 413-433.		1
549	Antithrombotika und Antihämorrhagika. , 2015, , 477-500.		1
550	Antithrombotika und Antihämorrhagika. , 2016, , 351-368.		2
551	Antithrombotika und Antihämorrhagika. , 2017, , 353-372.		1
552	Antithrombotika und Antihämorrhagika. , 2018, , 401-421.		3
553	Antithrombotika und Antihämorrhagika. , 2019, , 531-555.		8
554	Management of cancer-associated venous thromboembolism – a case-based practical approach. <i>Vasa - European Journal of Vascular Medicine</i> , 2018, 47, 77-89.	1.4	15

#	ARTICLE	IF	CITATIONS
555	Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Answers to Challenging “Real-World” Questions. <i>Thrombosis</i> , 2012, 2012, 1-10.	1.4	4
556	Novel oral anticoagulants for atrial fibrillation. <i>Singapore Medical Journal</i> , 2015, 56, 657-659.	0.6	14
557	Pharmacologic tools to reduce bleeding in surgery. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 517-21.	2.5	19
558	Assessment and management of massive bleeding: coagulation assessment, pharmacologic strategies, and transfusion management. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 522-8.	2.5	7
559	Pharmacologic tools to reduce bleeding in surgery. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 517-521.	2.5	27
560	Assessment and management of massive bleeding: coagulation assessment, pharmacologic strategies, and transfusion management. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 522-528.	2.5	19
561	How Safe is Dabigatran in Elderly?. <i>Gazi Medical Journal</i> , 2016, 27, .	0.0	1
562	The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation “ A Brief Summary. <i>Arrhythmia and Electrophysiology Review</i> , 2013, 2, 115.	2.4	2
563	IDARUCIZUMAB, A SPECIFIC REVERSAL AGENT FOR DABIGATRAN: THE PRESENT-DAY KNOWLEDGE. <i>Atherothrombosis</i> , 2018, , 147-157.	0.3	2
564	Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies. <i>Current Vascular Pharmacology</i> , 2011, 9, 763-769.	1.7	22
565	Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease. <i>Current Cardiology Reviews</i> , 2015, 11, 261-269.	1.5	27
566	Dabigatran Etxilate : Pharmacology of the New, Oral Direct Thrombin Inhibitor. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2011, 22, 143-150.	0.1	1
567	Novel Oral Anticoagulants for VTE Prevention in Orthopedic Surgery: Overview of Phase 3 Trials. <i>Orthopedics</i> , 2011, 34, 795-804.	1.1	14
568	Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. <i>Cleveland Clinic Journal of Medicine</i> , 2013, 80, 443-451.	1.3	61
569	When patients on target-specific oral anticoagulants need surgery. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 629-639.	1.3	8
570	Practical issues in the management of novel oral anticoagulants-cardioversion and ablation. <i>Journal of Thoracic Disease</i> , 2015, 7, 115-31.	1.4	8
571	Update on the status of new oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Cardiovascular Medicine(Switzerland)</i> , 2013, 16, 103-114.	0.0	7
572	Direct oral anticoagulants: a guide for daily practice. <i>Swiss Medical Weekly</i> , 2016, 146, w14286.	1.6	11

#	ARTICLE	IF	CITATIONS
573	New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. World Journal of Orthopedics, 2014, 5, 188.	1.8	5
574	Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation. Journal of Stroke, 2013, 15, 144.	3.2	9
575	Anticoagulation: Where have we come from and where are we going? The evidence for and against novel anticoagulants. South African Medical Journal, 2014, 104, 143.	0.6	1
576	Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions. Drugs in Context, 2013, 2013, 1-6.	2.2	5
577	Dabigatran for prophylaxis of thromboembolic events in patients with atrial fibrillation. Research Reports in Clinical Cardiology, 0, , 11.	0.2	0
579	The analyses of patients whose APTT were prolonged by the administration of dabigatran etexilate. Nosotchu, 2012, 34, 435-439.	0.1	0
580	New anticoagulants for the prevention and therapy of venous thromboembolism- a review. Cardiovascular Medicine(Switzerland), 2012, 15, 147-154.	0.0	0
582	Lowering the Risk for Thrombus and Stroke in Atrial Fibrillation Patients: Will Dabigatran Replace Warfarin?. Clinical Medicine Reviews in Vascular Health, 2013, 5, 1-8.	3.0	0
583	Anticoagulation Therapy. Heparins, Factor II and Factor Xa Inhibitors. , 2014, , 59-122.		0
584	Adjunctive Pharmacology for Coronary Intervention. , 2014, , 143-156.		0
586	Novel Oral Anticoagulants for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation. , 2014, , 55-89.		0
587	Newer Oral Anticoagulants. , 2014, , 237-248.		0
588	Antithrombotika und Antihämorrhagika. , 2014, , 469-490.		0
589	Emergent Reversal of Oral Anticoagulation: Review of Current Treatment Strategies. AACN Advanced Critical Care, 2014, 25, 5-12.	1.1	0
591	Risk Factors for the Prolongation of Activated Partial Thromboplastin Time Associated with Dabigatran Therapy in Patients with Non-Valvular Atrial Fibrillation. Japanese Journal of Clinical Pharmacology and Therapeutics, 2015, 46, 179-184.	0.1	0
592	Venous Thromboembolism Prevention and the Role of Non-Coumarin Oral Anticoagulants in the Intensive Care Units. , 2016, , 167-178.		0
593	Reversal of Dabigatran with Idarucizumab. Expert Review of Cardiovascular Therapy, 2016, 14, 889-893.	1.5	1
594	Management of Bleeding with Non Vitamin K Oral Anticoagulants. Journal of Cardiology & Current Research, 2016, 7, .	0.1	0

#	ARTICLE	IF	CITATIONS
595	Dabigatran - clinical evidence for treatment in patients with thromboembolism. Klinicka Farmakologie A Farmacie, 2016, 30, 15-17.	0.2	1
596	Management of Acute Upper Gastrointestinal Hemorrhage. , 2017, , 527-533.		0
597	Anticoagulants for Atrial Fibrillation. Cardiovascular Medicine, 2017, , 105-114.	0.0	0
599	Peri-operative care of patients with antikoagulation therapy. Intervencni A Akutni Kardiologie, 2017, 16, 18-22.	0.0	0
600	Recent Advances for Stroke Prevention in Patients With Atrial Fibrillation and Advanced Kidney Disease. , 2019, , 736-740.e2.		0
601	Reversal of Anticoagulants in Critical Care. Indian Journal of Critical Care Medicine, 2019, 23, 0-0.	0.9	0
604	Manejo das Hemorragias Relacionadas aos Anticoagulantes Orais de Ação Direta. Journal of Cardiac Arrhythmias, 2019, 32, 89-96.	0.1	0
605	Management of Hemorrhage Related to Direct Action Oral Anticoagulant Medication. Journal of Cardiac Arrhythmias, 2019, 32, 89-96.	0.1	0
606	Antithrombotika und Antihämorrhagika. , 2020, , 395-420.		0
608	Advances and Application of a Novel Oral Anticoagulant in Specific Populations: Dabigatran Etxilate. Current Drug Metabolism, 2020, 21, 106-111.	1.2	0
609	Impact of Renal Function on Effectiveness and Safety Associated With Low Dose Dabigatran in Non-valve Atrial Fibrillation Patients After Catheter Ablation. Frontiers in Cardiovascular Medicine, 2021, 8, 762872.	2.4	0
610	The prevention and treatment of bleeding associated with direct oral anticoagulants. Klinicheskaia Meditsina, 2020, 96, 491-497.	0.1	0
611	Safety of dabigatran in patients with atrial fibrillation and chronic kidney disease: pharmacokinetic and pharmacogenetic aspects. Meditsinskiy Sovet, 2020, , 65-73.	0.5	0
612	Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review. Cardiovascular Diagnosis and Therapy, 2014, 4, 224-31.	1.7	11
613	Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. P and T, 2014, 39, 858-80.	0.9	6
614	My Patient Taking A Novel Oral Anticoagulant Needs Surgery, Device Implantation, Or Ablation. Journal of Atrial Fibrillation, 2014, 7, 1145.	0.5	1
615	How we treat bleeding associated with direct oral anticoagulants. Blood Transfusion, 2016, 14, 465-73.	0.4	8
616	Periprocedural Management of Non-Vitamin K Oral Anticoagulants in Chronic Kidney Disease: A Review of Existing Heterogeneity and Contemporary Evidence. Journal of Atrial Fibrillation, 2015, 8, 1230.	0.5	1

#	ARTICLE	IF	CITATIONS
617	Apixaban in patients with Atrial Fibrillation: A Systematic Review. Journal of Atrial Fibrillation, 2012, 5, 499.	0.5	0
618	Use of direct oral anticoagulants in ICU patients. Part I – Applied pharmacology. Anaesthesiology Intensive Therapy, 2021, 53, 429-439.	1.0	3
619	Anticoagulants in the Management of Pulmonary Embolism. , 0, , .		2
620	Antithrombotika und Antihämorrhagika. , 2021, , 299-326.		3
621	Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran. Pharmaceutics, 2022, 14, 257.	4.5	2
622	Healthcare Resource Utilization for Oral Anticoagulant Reversal Therapies in Non-Valvular Atrial Fibrillation/Venous Thromboembolism Patients. Cardiology Research, 2022, 13, 27-43.	1.1	2
623	Idarucizumab reverses dabigatran-induced anticoagulation in treatment of gastric bleeding: A case report. World Journal of Clinical Cases, 2022, 10, 2537-2542.	0.8	1
630	Evaluating pharmacokinetic drug-drug interactions of direct oral anticoagulants in patients with renal dysfunction. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 189-202.	3.3	2
631	Clinical Implications of Altered Drug Transporter Abundance/Function and <scp>PBPK</scp> Modeling in Specific Populations: An <scp>ITC</scp> Perspective. Clinical Pharmacology and Therapeutics, 2022, 112, 501-526.	4.7	21
632	Anticoagulants: dose control methods and inhibitors. Obstetrics, Gynecology and Reproduction, 2022, 16, 158-175.	0.5	2
633	Drug Interactions Affecting Oral Anticoagulant Use. Circulation: Arrhythmia and Electrophysiology, 2022, 15, .	4.8	13
634	The use of non-vitamin K oral anticoagulants in dialysis patients – A systematic review. Seminars in Dialysis, 2022, 35, 463-480.	1.3	4
635	Delayed Concentration Effect Models for Dabigatran Anticoagulation. Paediatric Anaesthesia, 0, , .	1.1	2
636	Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants and Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase. JAMA - Journal of the American Medical Association, 2022, 327, 2354.	7.4	0
637	Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, .	3.7	4
638	A Historical Perspective on the Reversal of Anticoagulants. Seminars in Thrombosis and Hemostasis, 0, , .	2.7	3
639	Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	3
641	The non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function – A systematic review. Vascular Pharmacology, 2022, 147, 107123.	2.1	2

#	ARTICLE	IF	CITATION
642	Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice. Heart Lung and Circulation, 2022, , .	0.4	0
643	Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes. Journal of Thrombosis and Thrombolysis, 0, , .	2.1	0
644	Effectiveness and safety of direct oral anticoagulants in patients with venous thromboembolism and creatinine clearance≤30 mL/min. Journal of Thrombosis and Thrombolysis, 2023, 55, 355-364.	2.1	3
645	äƒ€äƒ“ä,~äƒ^äƒ©äƒ³éŽéžœœè—ä«â~¼ä~ªā,ä,äƒ€äƒ«ä,ä,°äƒžäƒ—ä®éªè,,^â†...æŠ•ä,Ži¼šè;€æ¼;ä,äƒ€äƒ“ä,~äƒ^äƒ©äƒ³æ¼fâº ä•	0.0	0
646	Antithrombotische Therapie. , 2022, , 233-263.		0
647	Gastrointestinal bleeding in patients under anticoagulant and antiplatelet therapy - the optimal approach. , 2022, 3, 37-48.		0
648	Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency. Advances in Therapy, 2023, 40, 4264-4281.	2.9	1
649	ANTICOAGULANT THERAPY FOR CHRONIC KIDNEY DISEASE AND ATRIAL FIBRILLATION: THE AXIS OF ROTATION BETWEEN THE POLES OF RISK. Eurasian Heart Journal, 2018, , 64-82.	0.8	0
650	Implications of direct oral anticoagulation and antiplatelet therapy in intensive care. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2020, 22, 181-188.	0.1	0
651	Treatment of dabigatran intoxication in critically ill patients with Acute Kidney Injury: The role of Sustained Low-Efficiency Dialysis. International Journal of Artificial Organs, 2023, 46, 574-580.	1.4	2
652	Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. Expert Opinion on Drug Metabolism and Toxicology, 2023, 19, 911-923.	3.3	0
653	2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2024, 149, .	1.6	41
654	2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Journal of the American College of Cardiology, 2024, 83, 109-279.	2.8	13
655	Dabigatran pharmacokinetic-pharmacodynamic in sheep: Informing dose for anticoagulation during cardiopulmonary bypass. Perfusion (United Kingdom), 0, , .	1.0	0
657	Efficacy and safety of anticoagulant for treatment and prophylaxis of VTE patients with renal insufficiency: a systemic review and meta-analysis. Thrombosis Journal, 2024, 22, .	2.1	0
658	Antithrombotische Therapie. , 2023, , 255-287.		0